Trust in the first-in-class treatment

BOTOX® was the first neurotoxin FDA approved for Blepharospasm in 19891

Hear about Blepharospasm patients from Dr. Alan Scott, one of the founders of BOTOX®.

A rare condition that severely impacts patients

Blepharospasm causes involuntary, repetitive spasms leading to eyelid closure.4

Rapid and significant symptom improvement with BOTOX® treatment

In an open label study, 93% of patients treated with BOTOX® showed an improvement within 48 hours post injection, and effect reached a peak at 1 or 2 weeks post treatment (n = 27).1

Proven dosing established more than 30 years ago

Used to treat Blepharospasm since 1989.1

Next Page